Jazz Pharmaceuticals

Jazz Pharmaceuticals JAZZ Stock

$230.26   -2.617891%
Add to favorites
Market Cap
$14.78B
LOW - HIGH [24H]
$227.95 - $238.59
VOLUME [24H]
$984.70K
P/E Ratio
68.12
Earnings per share
$3.38
ISIN
IE00B4Q5ZN47
Price   Prediction

Jazz Pharmaceuticals Price Chart

Sorry, that's all we've gotfor now...

Jazz Pharmaceuticals (JAZZ) stock price today is 230.26 USD on Tech Market Large (-2.62% on the day). Updated .

Jazz Pharmaceuticals JAZZ Financial and Trading Overview

Jazz Pharmaceuticals stock price 230.26 USD
Previous Close 236.45 USD
Open 235.19 USD
Bid 216.25 USD x 200
Ask 255.61 USD x 200
Day's Range 227.95 - 238.59 USD
52 Week Range 156.95 - 266.38 USD
Volume 984.64K USD
Avg. Volume 897.76K USD
Market Cap 14.78B USD
Beta (5Y Monthly) 0.371
PE Ratio (TTM) 68.12426
EPS (TTM) 3.38 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 297.5 USD

JAZZ Valuation Measures

Enterprise Value 17.97B USD
Trailing P/E 68.12426
Forward P/E 8.6101675
PEG Ratio (5 yr expected) 0.96
Price/Sales (ttm) 3.1325963
Price/Book (mrq) 3.5210643
Enterprise Value/Revenue 3.808
Enterprise Value/EBITDA 8.935

Trading Information

Jazz Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.371
52-Week Change 33.64%
S&P500 52-Week Change 8.67%
52 Week High 266.38 USD
52 Week Low 156.95 USD
50-Day Moving Average 229.05 USD
200-Day Moving Average 221.53 USD

JAZZ Share Statistics

Avg. Volume (3 month) 897.76K USD
Avg. Daily Volume (10-Days) 717.28K USD
Shares Outstanding 64.19M
Float 62.25M
Short Ratio 7.02
% Held by Insiders 2.97%
% Held by Institutions 106.57%
Shares Short 5.8M
Short % of Float 9.30%
Short % of Shares Outstanding 9.02%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 4.36%
Operating Margin (ttm) 27.38%
Gross Margin 91.10%
EBITDA Margin 42.61%

Management Effectiveness

Return on Assets (ttm) 6.91%
Return on Equity (ttm) 5.05%

Income Statement

Revenue (ttm) 4.72B USD
Revenue Per Share (ttm) 75.24 USD
Quarterly Revenue Growth (yoy) 10.40%
Gross Profit (ttm) 4.3B USD
EBITDA 2.01B USD
Net Income Avi to Common (ttm) 205.95M USD
Diluted EPS (ttm) 3.38
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 2.86B USD
Total Cash Per Share (mrq) 44.5 USD
Total Debt (mrq) 5.65B USD
Total Debt/Equity (mrq) 134.67 USD
Current Ratio (mrq) 1.821
Book Value Per Share (mrq) 65.395

Cash Flow Statement

Operating Cash Flow (ttm) 1.69B USD
Levered Free Cash Flow (ttm) 1.68B USD

Profile of Jazz Pharmaceuticals

Country United States
State N/A
City Dublin
Address Waterloo Exchange
ZIP D04 E5W7
Phone 353 1 634 7800
Website https://www.jazzpharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 2890

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Q&A For Jazz Pharmaceuticals Stock

What is a current JAZZ stock price?

Jazz Pharmaceuticals JAZZ stock price today per share is 230.26 USD.

How to purchase Jazz Pharmaceuticals stock?

You can buy JAZZ shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Jazz Pharmaceuticals?

The stock symbol or ticker of Jazz Pharmaceuticals is JAZZ.

Which industry does the Jazz Pharmaceuticals company belong to?

The Jazz Pharmaceuticals industry is Biotechnology.

How many shares does Jazz Pharmaceuticals have in circulation?

The max supply of Jazz Pharmaceuticals shares is 64.19M.

What is Jazz Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Jazz Pharmaceuticals PE Ratio is 68.12426000 now.

What was Jazz Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Jazz Pharmaceuticals EPS is 3.38 USD over the trailing 12 months.

Which sector does the Jazz Pharmaceuticals company belong to?

The Jazz Pharmaceuticals sector is Healthcare.

Jazz Pharmaceuticals JAZZ included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD US 2100.38 AUD 1467.26 USD
<0.01
— — 2100.38 AUD 1467.26 USD 2100.38 AUD 1467.26 USD — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us NYSE Arca Pharmaceutical Index DRG US 1315.95 USD —
+0.14
— — 1312.54 USD — 1336.79 USD — — — —
us US Tech Biotechnology Total Retu XNBI US 7414.87 USD —
-1.68
— — 7398.95 USD — 7631.86 USD — — — —
us US Tech US Smart Pharmaceuticals NQSSPH US 2214.31 USD —
-0.8
— — 2209.33 USD — 2262.42 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3419.87 USD —
-3.87
— — 3408.51 USD — 3548.76 USD — — — —
us US Tech Next Generation 100 Inde NGX US 1607.36 USD —
-3.42
— — 1601.83 USD — 1668.4 USD — — — —
us US Tech Biotechnology NBI US 6781.89 USD —
-1.73
— — 6767.31 USD — 6980.47 USD — — — —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
us US Tech Composite Total Return XCMP US 27958.09 USD —
-5.28
— — 27828.65 USD — 29466.09 USD — — — —
us US Tech Global Select Market Com NQGS US 11139.01 USD —
-5.31
— — 11086.73 USD — 11742.47 USD — — — —
$2.08T
Total marketcap
$58.85B
Total volume
BTC 58.74%   •   ETH 10.08%
Dominance
Select currency